Aprea Therapeutics, Inc. (NASDAQ:APRE) has received a consensus rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.25.
A number of research firms recently commented on APRE. Berenberg Bank assumed coverage on Aprea Therapeutics in a research report on Wednesday, December 16th. They set a “buy” rating and a $37.00 price target on the stock. Zacks Investment Research raised shares of Aprea Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 2nd. HC Wainwright reiterated a “neutral” rating and set a $6.00 target price (down from $30.00) on shares of Aprea Therapeutics in a research report on Tuesday, December 29th. Morgan Stanley dropped their price objective on shares of Aprea Therapeutics from $34.00 to $6.00 in a research report on Tuesday, December 29th. Finally, Robert W. Baird lowered Aprea Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, December 28th.
A number of institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Aprea Therapeutics in the third quarter valued at approximately $46,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Aprea Therapeutics during the 4th quarter worth about $35,000. Squarepoint Ops LLC acquired a new position in Aprea Therapeutics in the 3rd quarter valued at about $225,000. Hershey Trust Co. bought a new position in Aprea Therapeutics in the 4th quarter valued at about $48,000. Finally, Jane Street Group LLC acquired a new stake in Aprea Therapeutics during the fourth quarter worth approximately $58,000. Institutional investors and hedge funds own 79.31% of the company’s stock.
Shares of APRE opened at $4.84 on Monday. The stock has a market cap of $102.55 million, a PE ratio of -1.98 and a beta of 0.10. Aprea Therapeutics has a 1 year low of $4.64 and a 1 year high of $41.12. The stock has a 50 day simple moving average of $5.73 and a 200-day simple moving average of $15.22.
Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Monday, March 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.05). As a group, analysts anticipate that Aprea Therapeutics will post -2.49 earnings per share for the current fiscal year.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.